CPL-01 (Cali Biosciences)

CPL-01 is an investigational, extended-release injectable formulation of ropivacaine hydrochloride, a member of the amino amide class of local anesthetics. Developed by Cali Biosciences using its proprietary PG-Depot drug delivery platform, CPL-01 is designed to provide sustained local analgesia for up to 72 hours following a single administration at the surgical site. It acts by reversibly blocking voltage-gated sodium channels, thereby inhibiting the influx of sodium ions and preventing the initiation and conduction of nerve impulses. CPL-01 is currently in Phase 3 clinical development for the management of postoperative pain (such as after open inguinal herniorrhaphy and bunionectomy) with the goal of reducing or eliminating the need for postoperative opioids.

Other names

extended-release ropivacainelocal anaesthetic injection of ropivacaine HCllocal anesthetic injection of CPL-01long-acting ropivacaineropivacaine hydrochloride extended-release